Compare Koninklijke Philips NV (PHG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs GeneDx Holdings Corp — how do they compare? Koninklijke Philips NV trades at $24.22 (market cap $23.52B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Koninklijke Philips NV is far larger — about 11.6× GeneDx Holdings Corp's market cap, and Koninklijke Philips NV pays a 4.17% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and GeneDx Holdings Corp for 19 Days on average.
| PHG | WGS | |
|---|---|---|
Market Cap | $23.52B | $2.02B |
Volume | 1,635,069 | 734,640 |
Sector | Health | Health |
52-Week High | $32.91 | $167.51 |
52-Week Low | $23.81 | $34.51 |
Typical Hold Time | 84 Days | 19 Days |
Enterprise Value | $29.87B | $2.05B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.24, up 0.62% today, amid a bearish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent financials show a return to profitability in 2025 with net income of $895 million, while cash flow from operations remains positive at $1.17 billion. Key developments include new product launches in healthcare imaging and a $33.7 million ARPA-H award for AI-enabled stroke care.
The outlook is mixed: strong earnings momentum and solid profitability metrics support upside, but technical weakness and a high 'Hold' analyst consensus suggest near-term caution. Risks include competitive pressures and debt levels, though institutional buying activity indicates underlying confidence.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
